Optimal First Line Therapy for Metastatic Melanoma: Nivolumab and Relatlimab

Discussing the efficacy and safety of Nivolumab and Relatlimab as a superior first-line therapy option for newly diagnosed metastatic melanoma patients, with comparisons to other treatments based on key endpoints and tolerability data presented at ASCO Annual Meeting.

0 views • 8 slides